Target- and mechanism-based therapeutics for neurodegenerative diseases: Strength in numbers

Journal of Medicinal Chemistry

Volumn 56, Issue 8, 2013, Pages 3121-3147

  Trippier, Paul C ^a,b   Jansen Labby, Kristin ^a,c   Hawker, Dustin D ^a   Mataka, Jan J ^a,d   Silverman, Richard B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d NORTHEASTERN ILLINOIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ARIMOCLOMOL; CEFTRIAXONE; DIMEBON; DIZOCILPINE; IFENPRODIL; ISRADIPINE; LEVODOPA; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEURONAL NITRIC OXIDE SYNTHASE; PLACEBO; REACTIVE OXYGEN METABOLITE; REMACEMIDE; RILUZOLE; TRAXOPRODIL; VOLTAGE GATED CALCIUM CHANNEL;

ACETYLATION; AEROBIC METABOLISM; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; CARBONYLATION; CONFUSION; CRYSTAL STRUCTURE; DEGENERATIVE DISEASE; DENSITY; DIMERIZATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DYSKINESIA; ESTROGEN THERAPY; EXCITOTOXICITY; GENE EXPRESSION; HALLUCINATION; HIGH THROUGHPUT SCREENING; HIPPOCAMPUS; HUMAN; HYPOTENSION; IC 50; INTRACELLULAR SIGNALING; LIPID PEROXIDATION; METABOLIC STRESS; METHYLATION; MITOCHONDRIAL MEMBRANE; MONOTHERAPY; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NITROSATIVE STRESS; NITROSYLATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTSYNAPTIC DENSITY; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANTS; CALCIUM CHANNELS; DRUG COMBINATIONS; DRUG DESIGN; HUMANS; HUNTINGTON DISEASE; NEURODEGENERATIVE DISEASES; NITRIC OXIDE SYNTHASE TYPE I; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN FOLDING; PROTEIN STRUCTURE, QUATERNARY; PROTEOSTASIS DEFICIENCIES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84876832340     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3015926     Document Type: Review

References (313)

1. Lin, M. T.; Beal, M. F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases Nature 2006, 443, 787-795
2. Hebert, L. E.; Scherr, P. A.; Bienias, J. L.; Bennett, D. A.; Evans, D. A. Alzheimer disease in the US population: prevalence estimates using the 2000 census Arch. Neurol. 2003, 60, 1119-1122
3. Wancata, J.; Musalek, M.; Alexandrowicz, R.; Krautgartner, M. Number of dementia sufferers in Europe between the years 2000 and 2050 Eur. Psychiatry 2003, 18, 306-313
4. Forman, M. S.; Trojanowski, J. Q.; Lee, V. M. Y. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs Nat. Med. 2004, 10, 1055-1063
5. Bossy-Wetzel, E.; Schwarzenbacher, R.; Lipton, S. A. Molecular pathways to neurodegeneration Nat. Med. 2004, 10 (Suppl.) S2-S9
6. Pardo, L. M.; van Duijn, C. M. In search of genes involved in neurodegenerative disorders Mutat. Res. 2005, 592, 89-101
7. Amor, S.; Puentes, F.; Baker, D.; van der Valk, P. Inflammation in neurodegenerative diseases Immunology 2010, 129, 154-169
8. Glass, C. K.; Saijo, K.; Winner, B.; Marchetto, M. C.; Gage, F. H. Mechanisms underlying inflammation in neurodegeneration Cell 2010, 140, 918-934
9. Czirr, E.; Wyss-Coray, T. The immunology of neurodegeneration J. Clin. Invest. 2012, 122, 1156-1163
10. Schwarcz, R.; Bruno, J. P.; Muchowski, P. J.; Wu, H. Q. Kynurenines in the mammalian brain: when physiology meets pathology Nat. Rev. Neurosci. 2012, 13, 465-477
11. Lugo-Huitron, R.; Blanco-Ayala, T.; Ugalde-Muniz, P.; Carrillo-Mora, P.; Pedraza-Chaverri, J.; Silva-Adaya, D.; Maldonado, P. D.; Torres, I.; Pinzon, E.; Ortiz-Islas, E.; Lopez, T.; Garcia, E.; Pineda, B.; Torres-Ramos, M.; Santamaria, A.; La Cruz, V. P. On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress Neurotoxicol. Teratol. 2011, 33, 538-547
12. Hanisch, U. K.; Johnson, T. V.; Kipnis, J. Toll-like receptors: roles in neuroprotection? Trends Neurosci 2008, 31, 176-182
13. Drouin-Ouellet, J.; Cicchetti, F. Inflammation and neurodegeneration: the story "retolled" Trends Pharmacol. Sci. 2012, 33, 542-551
14. Aquilano, K.; Baldelli, S.; Rotilio, G.; Ciriolo, M. R. Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols Neurochem. Res. 2008, 33, 2416-2426
15. Frank-Cannon, T. C.; Alto, L. T.; McAlpine, F. E.; Tansey, M. G. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol. Neurodegener. 2009, 4, 47
16. Mosley, R. L.; Gendelman, H. E. Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders Exp. Neurol. 2010, 222, 1-5
17. Neymotin, A.; Petri, S.; Calingasan, N. Y.; Wille, E.; Schafer, P.; Stewart, C.; Hensley, K.; Beal, M. F.; Kiaei, M. Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis Exp. Neurol. 2009, 220, 191-197
18. Greenfield, S.; Vaux, D. J. Parkinson's disease, Alzheimer's disease and motor neurone disease: identifying a common mechanism Neuroscience 2002, 113, 485-492
19. Calne, D. B.; Mcgeer, E.; Eisen, A.; Spencer, P. Alzheimers-disease, Parkinsons-disease, and Motoneuron disease-abiotropic interaction between aging and environment Lancet 1986, 2, 1067-1070
20. Cooper-Knock, J.; Kirby, J.; Ferraiuolo, L.; Heath, P. R.; Rattray, M.; Shaw, P. J. Gene expression profiling in human neurodegenerative disease Nat. Rev. Neurol. 2012, 8, 518-530
21. Cramer, P. E.; Cirrito, J. R.; Wesson, D. W.; Lee, C. Y.; Karlo, J. C.; Zinn, A. E.; Casali, B. T.; Restivo, J. L.; Goebel, W. D.; James, M. J.; Brunden, K. R.; Wilson, D. A.; Landreth, G. E. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models Science 2012, 335, 1503-1506
22. Graff, J.; Rei, D.; Guan, J. S.; Wang, W. Y.; Seo, J.; Hennig, K. M.; Nieland, T. J.; Fass, D. M.; Kao, P. F.; Kahn, M.; Su, S. C.; Samiei, A.; Joseph, N.; Haggarty, S. J.; Delalle, I.; Tsai, L. H. An epigenetic blockade of cognitive functions in the neurodegenerating brain Nature 2012, 483, 222-226
23. Jellinger, K. A. Recent advances in our understanding of neurodegeneration J. Neural Transm. 2009, 116, 1111-1162
24. Salloway, S.; Mintzer, J.; Weiner, M. F.; Cummings, J. L. Disease-modifying therapies in Alzheimer's disease Alzheimer's Dementia 2008, 4, 65-79
25. Zimmermann, G. R.; Lehar, J.; Keith, C. T. Multi-target therapeutics: when the whole is greater than the sum of the parts Drug Discovery Today 2007, 12, 34-42
26. De Raedt, T.; Walton, Z.; Yecies, J. L.; Li, D.; Chen, Y.; Malone, C. F.; Maertens, O.; Jeong, S. M.; Bronson, R. T.; Lebleu, V.; Kalluri, R.; Normant, E.; Haigis, M. C.; Manning, B. D.; Wong, K. K.; Macleod, K. F.; Cichowski, K. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors Cancer Cell 2011, 20, 400-413
27. McHutchison, J. G.; Manns, M.; Patel, K.; Poynard, T.; Lindsay, K. L.; Trepo, C.; Dienstag, J.; Lee, W. M.; Mak, C.; Garaud, J. J.; Albrecht, J. K. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 2002, 123, 1061-1069
28. Ho, D. D. Time to hit HIV, early and hard N. Engl. J. Med. 1995, 333, 450-451
29. Kihara, T.; Ikeda, M. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex J. Pharmacol. Exp. Ther. 1995, 272, 177-183
30. Delgado, P. L.; Moreno, F. A. Role of norepinephrine in depression J. Clin. Psychiatry 2000, 61 (Suppl. 1) 5-12
31. Traynelis, S. F.; Wollmuth, L. P.; McBain, C. J.; Menniti, F. S.; Vance, K. M.; Ogden, K. K.; Hansen, K. B.; Yuan, H.; Myers, S. J.; Dingledine, R. Glutamate receptor ion channels: structure, regulation, and function Pharmacol. Rev. 2010, 62, 405-496
32. Lipton, S. A.; Rosenberg, P. A. Excitatory amino-acids as a final common pathway for neurologic disorders N. Engl. J. Med. 1994, 330, 613-622
33. Lynch, D. R.; Guttmann, R. P. Excitotoxicity: perspectives based on N -methyl- d -aspartate receptor subtypes J. Pharmacol. Exp. Ther. 2002, 300, 717-723
34. Waxman, E. A.; Lynch, D. R. N -Methyl- d -aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease Neuroscientist 2005, 11, 37-49
35. 2+ accumulation in cortical cell culture correlates with subsequent neuronal degeneration J. Neurosci. 1993, 13, 1993-2000
36. Rothstein, J. D. Excitotoxicity hypothesis Neurology 1996, 47, 19S-26S
37. Hedegaard, M. K.; Hansen, K. B.; Andersen, K. T.; Bräuner-Osborne, H.; Traynelis, S. F. Molecular pharmacology of human NMDA receptors Neurochem. Int. 2012, 61, 601-609
38. Papouin, T.; Ladepeche, L.; Ruel, J.; Sacchi, S.; Labasque, M.; Hanini, M.; Groc, L.; Pollegioni, L.; Mothet, J. P.; Oliet, S. H. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists Cell 2012, 150, 633-646
39. Kemp, J. A.; McKernan, R. M. NMDA receptor pathways as drug targets Nat. Neurosci. 2002, 5, 1039-1042
40. Paoletti, P.; Neyton, J. NMDA receptor subunits: function and pharmacology Curr. Opin. Pharmacol. 2007, 7, 39-47
41. Beal, M. F. Aging, energy, and oxidative stress in neurodegenerative diseases Ann. Neurol. 1995, 38, 357-366
42. Coyle, J. An animal model for Huntington's disease Biol. Psychiatry 1979, 14, 251-276
43. Fan, M. M. Y.; Raymond, L. A. N -Methyl- d -aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease Prog. Neurobiol. 2007, 81, 272-293
44. Good, P. F.; Werner, P.; Hsu, A.; Olanow, C. W.; Perl, D. P. Evidence of neuronal oxidative damage in Alzheimer's disease Am. J. Pathol. 1996, 149, 21-28
45. Plaitakis, A. Glutamate dysfunction and selective motor neuron degeneration inamyotrophic lateral sclerosis: a hypothesis Ann. Neurol. 1990, 28, 3-8
46. Rothstein, J. D.; Martin, L. J.; Kuncl, R. W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis N. Engl. J. Med. 1992, 326, 1464-1468
47. Rothstein, J. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis Clin. Neurosci. 1996, 3, 348-359
48. Kalia, L. V.; Kalia, S. K.; Salter, M. W. NMDA receptors in clinical neurology: excitatory times ahead Lancet Neurol. 2008, 7, 742-755
49. Monaghan, D. T.; Irvine, M. W.; Costa, B. M.; Fang, G.; Jane, D. E. Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators Neurochem. Int. 2012, 61, 581-592
50. Evans, R.; Francis, A.; Jones, A.; Smith, D.; Watkins, J. The effects of a series of omega-phosphonic alpha-carboxylic amino acids on electrically evoked and excitant amino acid-induced responses in isolated spinal cord preparations Br. J. Pharmacol. 1982, 75, 65-75
51. Ogden, K. K.; Traynelis, S. F. New advances in NMDA receptor pharmacology Trends Pharmacol. Sci. 2011, 32, 726-733
52. Löschmann, P. A.; Lange, K.; Kunow, M.; Rettig, K. J.; Jähnig, P.; Honore, T.; Turski, L.; Wachtel, H.; Jenner, P.; Marsden, C. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease J. Neural Transm.: Parkinson's Dis. Dementia Sect. 1991, 3, 203-213
53. Veender, J. R.; Nair, S. N.; Lehmann, J. C. NMDA receptors: the first decade Expert Opin. Invest. Drugs 1994, 3, 341-354
54. Bräuner-Osborne, H.; Egebjerg, J.; Nielsen, E. O.; Madsen, U.; Krogsgaard-Larsen, P. Ligands for glutamate receptors: design and therapeutic prospects J. Med. Chem. 2000, 43, 2609-2645
55. Lehmann, J. C.; Wood, P. L. 7-Chlorokynurenate prevents NMDA-induced and kainate-induced striatal lesions Brain Res. 1993, 620, 1-6
56. Wong, E.; Kemp, J. A.; Priestley, T.; Knight, A. R.; Woodruff, G. N.; Iversen, L. L. The anticonvulsant MK-801 is a potent N -methyl- d -aspartate antagonist Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 7104-7108
57. Marin, C.; Papa, S.; Engber, T. M.; Bonastre, M.; Tolosa, E.; Chase, T. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats Brain Res. 1996, 736, 202-205
58. Chen, H. S. V.; Lipton, S. A. The chemical biology of clinically tolerated NMDA receptor antagonists J. Neurochem. 2006, 97, 1611-1626
59. Crossman, A.; Peggs, D.; Boyce, S.; Luquin, M.; Sambrook, M. Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey Neuropharmacology 1989, 28, 1271-1273
60. Blanpied, T. A.; Clarke, R. J.; Johnson, J. W. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block J. Neurosci. 2005, 25, 3312-3322
61. Uitti, R.; Rajput, A.; Ahlskog, J.; Offord, K.; Schroeder, D.; Ho, M.; Prasad, M.; Rajput, A.; Basran, P. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease Neurology 1996, 46, 1551-1556
62. Metman, V. L.; Dotto, D. P.; Natte, R.; Van den Munckhof, P.; Chase, T. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease Neurology 1998, 51, 203-206
63. Metman, L. V.; Del Dotto, P.; LePoole, K.; Konitsiotis, S.; Fang, J.; Chase, T. N. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study Arch. Neurol. 1999, 56, 1383-1386
64. Crosby, N.; Deane, K.; Clarke, C. Amantadine for dyskinesia in Parkinson's disease Cochrane Database Syst. Rev. 2003, 2, 1-14
65. Shoulson, I.; Penney, J.; McDermott, M.; Schwid, S.; Kayson, E.; Chase, T.; Fahn, S.; Greenamyre, J.; Lang, A.; Siderowf, A. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease Neurology 2001, 56, 455-462
66. Lipton, S. A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond Nat. Rev. Drug Discovery 2006, 5, 160-170
67. Ferris, S. H. Evaluation of memantine for the treatment of Alzheimer's disease Expert Opin. Pharmacother. 2003, 4, 2305-2313
68. Herrmann, N.; Li, A.; Lanctoot, K. Memantine in dementia: a review of the current evidence Expert Opin. Pharmacother. 2011, 12, 787-800
69. Lipton, S. A. Pathologically activated therapeutics for neuroprotection Nat. Rev. Neurosci. 2007, 8, 803-808
70. Williams, K. Ifenprodil discriminates subtypes of the N -methyl- d -aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors Mol. Pharmacol. 1993, 44, 851-859
71. Tahirovic, Y. A.; Geballe, M.; Gruszecka-Kowalik, E.; Myers, S. J.; Lyuboslavsky, P.; Le, P.; French, A.; Irier, H.; Choi, W.; Easterling, K. Enantiomeric propanolamines as selective N -methyl- d -aspartate 2B receptor antagonists J. Med. Chem. 2008, 51, 5506-5521
72. Mosley, C. A.; Myers, S. J.; Murray, E. E.; Santangelo, R.; Tahirovic, Y. A.; Kurtkaya, N.; Mullasseril, P.; Yuan, H.; Lyuboslavsky, P.; Le, P. Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N -methyl- d -aspartate receptors Bioorg. Med. Chem. 2009, 17, 6463-6480
73. Fischer, G.; Mutel, V.; Trube, G.; Malherbe, P.; Kew, J.; Mohacsi, E.; Heitz, M.; Kemp, J. Ro 25-6981, a highly potent and selective blocker of N -methyl- d -aspartate receptors containing the NR2B subunit. Characterization in vitro J. Pharmacol. Exp. Ther. 1997, 283, 1285-1292
74. Taniguchi, K.; Shinjo, K.; Mizutani, M.; Shimada, K.; Ishikawa, T.; Menniti, F. S.; Nagahisa, A. Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist Br. J. Pharmacol. 1997, 122, 809-812
75. Nutt, J. G.; Gunzler, S. A.; Kirchhoff, T.; Hogarth, P.; Weaver, J. L.; Krams, M.; Jamerson, B.; Menniti, F. S.; Landen, J. W. Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism Mov. Disord. 2008, 23, 1860-1866
76. Mosley, C. A.; Acker, T. M.; Hansen, K. B.; Mullasseril, P.; Andersen, K. T.; Le, P.; Vellano, K. M.; Bräuner-Osborne, H.; Liotta, D. C.; Traynelis, S. F. Quinazolin-4-one derivatives: a novel class of noncompetitive NR2C/D subunit-selective N -methyl- d -aspartate receptor antagonists J. Med. Chem. 2010, 5476-5490
77. Hansen, K. B.; Traynelis, S. F. Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors J. Neurosci. 2011, 31, 3650-3661
78. Costa, B. M.; Irvine, M. W.; Fang, G.; Eaves, R. J.; Mayo-Martin, M. B.; Skifter, D. A.; Jane, D. E.; Monaghan, D. T. A novel family of negative and positive allosteric modulators of NMDA receptors J. Pharmacol. Exp. Ther. 2010, 335, 614-621
79. Acker, T. M.; Yuan, H.; Hansen, K. B.; Vance, K. M.; Ogden, K. K.; Jensen, H. S.; Burger, P. B.; Mullasseril, P.; Snyder, J. P.; Liotta, D. C. Mechanism for noncompetitive inhibition by novel GluN2C/D N -methyl- d -aspartate receptor subunit-selective modulators Mol. Pharmacol. 2011, 80, 782-795
80. Bettini, E.; Sava, A.; Griffante, C.; Carignani, C.; Buson, A.; Capelli, A. M.; Negri, M.; Andreetta, F.; Senar-Sancho, S. A.; Guiral, L. Identification and characterization of novel NMDA receptor antagonists selective for NR2A-over NR2B-containing receptors J. Pharmacol. Exp. Ther. 2010, 335, 636-644
81. Retchless, B. S.; Gao, W.; Johnson, J. W. A single GluN2 subunit residue controls NMDA receptor channel properties via intersubunit interaction Nat. Neurosci. 2012, 15, 406-413
82. Neyton, J.; Paoletti, P. Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach J. Neurosci. 2006, 26, 1331-1333
83. Hatton, C. J.; Paoletti, P. Modulation of triheteromeric NMDA receptors by N-terminal domain ligands Neuron 2005, 46, 261-274
84. Xia, P.; Chen, H. V.; Zhang, D.; Lipton, S. A. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses J. Neurosci. 2010, 30, 11246-11250
85. Okamoto, S.; Pouladi, M. A.; Talantova, M.; Yao, D.; Xia, P.; Ehrnhoefer, D. E.; Zaidi, R.; Clemente, A.; Kaul, M.; Graham, R. K. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin Nat. Med. 2009, 15, 1407-1413
86. Hardingham, G. E.; Bading, H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders Nat. Rev. Neurosci. 2010, 11, 682-696
87. Levine, M. S.; Cepeda, C.; André, V. M. Location, location, location: contrasting roles of synaptic and extrasynaptic NMDA receptors in Huntington's disease Neuron 2010, 65, 145-147
88. Surmeier, D. J.; Guzman, J. N.; Sanchez-Padilla, J.; Goldberg, J. A. The origins of oxidant stress in Parkinson's disease and therapeutic strategies Antioxid. Redox Signaling 2011, 14, 1289-1301
89. Youdim, M.; Buccafusco, J. CNS targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases J. Neural Transm. 2005, 112, 519-537
90. Youdim, M. B. H.; Geldenhuys, W. J.; Van der Schyf, C. J. Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease? Parkinsonism Relat. Disord. 2007, 13, S281-S291
91. Geldenhuys, W. J.; Youdim, M. B. H.; Carroll, R. T.; Van der Schyf, C. J. The emergence of designed multiple ligands for neurodegenerative disorders Prog. Neurobiol. 2011, 347-359
92. Wu, J.; Li, Q.; Bezprozvanny, I. Evaluation of Dimebon in cellular model of Huntington's disease Mol. Neurodegener. 2008, 3, 15
93. Jones, R. W. Dimebon disappointment Alzheimer's Res. Ther. 2010, 2, 25
94. 2+ channels Bull. Exp. Biol. Med. 2001, 132, 1079-1083
95. Grigor'ev, V.; Dranyi, O.; Bachurin, S. Comparative study of action mechanisms of dimebon and memantine on AMPA-and NMDA-subtypes glutamate receptors in rat cerebral neurons Bull. Exp. Biol. Med. 2003, 136, 474-477
96. Blandini, F. An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease Funct. Neurol. 2010, 25, 65-71
97. Waldmeier, P.; Bozyczko-Coyne, D.; Williams, M.; Vaught, J. L. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases Biochem. Pharmacol. 2006, 72, 1197-1206
98. Kim, H. S.; Suh, Y. H. Minocycline and neurodegenerative diseases Behav. Brain Res. 2009, 196, 168-179
99. X Sureda, F.; Junyent, F.; Verdaguer, E.; Auladell, C.; Pelegri, C.; Vilaplana, J.; Folch, J.; Maria Canudas, A.; Beas Zarate, C.; Pallas, M. Antiapoptotic drugs: a therapeutic strategy for the prevention of neurodegenerative diseases Curr. Pharm. Des. 2011, 17, 230-245
100. Malgouris, C.; Daniel, M.; Doble, A. Neuroprotective effects of riluzole on N -methyl- d -aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices Neurosci. Lett. 1994, 177, 95-99
101. Doble, A. The pharmacology and mechanism of action of riluzole Neurology 1996, 47, 233S-241S
102. Bryson, H. M.; Fulton, B.; Benfield, P. Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis Drugs 1996, 52, 549-563
103. Jankovic, J.; Hunter, C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease Parkinsonism Relat. Disord. 2002, 8, 271-276
104. Landwehrmeyer, G. B.; Dubois, B.; de Yébenes, J. G.; Kremer, B.; Gaus, W.; Kraus, P. H.; Przuntek, H.; Dib, M.; Doble, A.; Fischer, W. Riluzole in Huntington's disease: a 3-year, randomized controlled study Ann. Neurol. 2007, 62, 262-272
105. Lee, S. G.; Su, Z. Z.; Emdad, L.; Gupta, P.; Sarkar, D.; Borjabad, A.; Volsky, D. J.; Fisher, P. B. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes J. Biol. Chem. 2008, 283, 13116-13123
106. Nicoletti, F.; Bruno, V.; Copani, A.; Casabona, G.; Knöpfel, T. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci. 1996, 19, 267-271
107. Caraci, F.; Battaglia, G.; Sortino, M. A.; Spampinato, S.; Molinaro, G.; Copani, A.; Nicoletti, F.; Bruno, V. Metabotropic glutamate receptors in neurodegeneration/neuroprotection: Still a hot topic? Neurochem. Int. 2012, 61, 559-565
108. Gregory, K. J.; Dong, E. N.; Meiler, J.; Conn, P. J. Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential Neuropharmacol. 2011, 60, 66-81
109. Striggow, F.; Ehrlich, B. E. Ligand-gated calcium channels inside and out Curr. Opin. Cell. Biol. 1996, 8, 490-495
110. Zamponi, G. W. Voltage-Gated Calcium Channels; Kluwer Academic: New York, 2005.
111. Berridge, M. J. Neuronal calcium signaling Neuron 1998, 21, 13-26
112. Catterall, W. A.; Striessnig, J.; Snutch, T. P.; Perez-Reyes, E. International Union of Pharmacology. XL. Compendium of voltage-gated ion channels: calcium channels Pharmacol. Rev. 2003, 55, 579-581
113. Eisenberg, M. J.; Brox, A.; Bestawros, A. N. Calcium channel blockers: an update Am. J. Med. 2004, 116, 35-43
114. 2+ channel isoforms for brain function Biochem. Soc. Trans. 2006, 34, 903-909
115. Helton, T. D.; Xu, W.; Lipscombe, D. Neuronal L-type calcium channels open quickly and are inhibited slowly J. Neurosci. 2005, 25, 10247-10251
116. Epstein, B. J.; Vogel, K.; Palmer, B. F. Dihydropyridine calcium channel antagonists in the management of hypertension Drugs 2007, 67, 1309-1327
117. Chan, C. S.; Guzman, J. N.; Ilijic, E.; Mercer, J. N.; Rick, C.; Tkatch, T.; Meredith, G. E.; Surmeier, D. J. "Rejuvenation" protects neurons in mouse models of Parkinson's disease Nature 2007, 447, 1081-1086
118. Brevetti, G.; Bonaduce, D.; Breglio, R.; Perna, S.; Simonelli, P.; Marconi, R.; Campanella, G. Parkinson's disease and hypotension: 24-hour blood pressure recording in ambulant patients Clin. Cardiol. 1990, 13, 474-478
119. Sinnegger-Brauns, M. J.; Huber, I. G.; Koschak, A.; Wild, C.; Obermair, G. J.; Einzinger, U.; Hoda, J. C.; Sartori, S. B.; Striessnig, J. Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms Mol. Pharmacol. 2009, 75, 407-414
120. Xu, W.; Lipscombe, D. Neuronal Ca(V)1.3alpha(1) L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines J. Neurosci. 2001, 21, 5944-5951
121. 2+ channels Ca V 1.3 and Ca V 1.2 Bioorg. Med. Chem. 2010, 18, 3147-3158
122. Sorkin, E. M.; Clissold, S. P.; Brogden, R. N. Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders Drugs 1985, 30, 182-274
123. Xia, G.; Benmohamed, R.; Kim, J.; Arvanites, A. C.; Morimoto, R. I.; Ferrante, R. J.; Kirsch, D. R.; Silverman, R. B. Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis J. Med. Chem. 2011, 54, 2409-2421
124. Kang, S.; Cooper, G.; Dunne, S. F.; Dusel, B.; Luan, C. H.; Surmeier, D. J.; Silverman, R. B. Ca(V)1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease Nat. Commun. 2012, 3, 1146
125. Nakamura, T.; Lipton, S. A. Cell death: protein misfolding and neurodegenerative diseases Apoptosis 2009, 14, 455-468
126. Chung, K. K. K.; David, K. K. Emerging roles of nitric oxide in neurodegeneration Nitric Oxide 2010, 22, 290-295
127. Giasson, B. I.; Duda, J. E.; Murray, I. V.; Chen, Q.; Souza, J. M.; Hurtig, H. I.; Ischiropoulos, H.; Trojanowski, J. Q.; Lee, V. M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions Science 2000, 290, 985-989
128. Chung, K. K. K.; Thomas, B.; Li, X.; Pletnikova, O.; Troncoso, J. C.; Marsh, L.; Dawson, V. L.; Dawson, T. M. S-Nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function Science 2004, 304, 1328-1331
129. Yao, D. D.; Gu, Z. Z.; Nakamura, T. T.; Shi, Z.-Q. Z.; Ma, Y. Y.; Gaston, B. B.; Palmer, L. A. L.; Rockenstein, E. M. E.; Zhang, Z. Z.; Masliah, E. E.; Uehara, T. T.; Lipton, S. A. S. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 10810-10814
130. Dawson, V. L.; Dawson, T. M. Nitric oxide in neurodegeneration Prog. Brain Res. 1998, 118, 215-229
131. Martínez-Ruiz, A.; Villanueva, L.; González de Orduña, C.; López-Ferrer, D.; Higueras, M. A.; Tarín, C.; Rodríguez-Crespo, I.; Vázquez, J.; Lamas, S. S-Nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 8525-8530
132. Tsang, A. H. K.; Chung, K. K. K. Oxidative and nitrosative stress in Parkinson's disease Biochim. Biophys. Acta 2009, 1792, 643-650
133. Daff, S. NO synthase: structures and mechanisms Nitric Oxide 2010, 23, 1-11
134. Erdal, E. P.; Litzinger, E. A.; Seo, J.; Zhu, Y.; Ji, H.; Silverman, R. B. Selective neuronal nitric oxide synthase inhibitors Curr. Top. Med. Chem. 2005, 5, 603-624
135. Furfine, E. S.; Harmon, M. F.; Paith, J. E.; Garvey, E. P. Selective inhibition of constitutive nitric oxide synthase by L-NG-nitroarginine Biochemistry 1993, 32, 8512-8517
136. Yamamoto, K.; Shimamura, K.; Sekiguchi, F.; Sunano, S. Effects of NG-nitro- l -arginine on the blood pressure of spontaneously hypertensive rats with different degrees of hypertension Clin. Exper. Hypertens. 2001, 23, 533-544
137. ω- nitroarginine- and phenylalanine-containing dipeptides and dipeptide esters J. Med. Chem. 1997, 40, 2813-2817
138. ω-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase J. Med. Chem. 1999, 42, 3147-3153
139. Huang, H.; Martásek, P.; Roman, L. J.; Silverman, R. B. Synthesis and evaluation of peptidomimetics as selective inhibitors and active site probes of nitric oxide synthases J. Med. Chem. 2000, 43, 2938-2945
140. Gómez-Vidal, J. A.; Martásek, P.; Roman, L. J.; Silverman, R. B. Potent and selective conformationally restricted neuronal nitric oxide synthase inhibitors J. Med. Chem. 2004, 47, 703-710
141. Hah, J.-M.; Roman, L. J.; Martásek, P.; Silverman, R. B. Reduced amide bond peptidomimetics. (4 S)- N -(4-Amino-5-[aminoakyl]aminopentyl)- N ′-nitroguanidines, potent and highly selective inhibitors of neuronal nitric oxide synthase J. Med. Chem. 2001, 44, 2667-2670
142. Hah, J.-M.; Martásek, P.; Roman, L. J.; Silverman, R. B. Aromatic reduced amide bond peptidomimetics as selective inhibitors of neuronal nitric oxide synthase J. Med. Chem. 2003, 46, 1661-1669
143. Crane, B. R.; Arvai, A. S.; Gachhui, R.; Wu, C.; Ghosh, D. K.; Getzoff, E. D.; Stuehr, D. J.; Tainer, J. A. The structure of nitric oxide synthase oxygenase domain and inhibitor complexes Science 1997, 278, 425-431
144. Raman, C. S.; Li, H.; Martásek, P.; Král, V.; Masters, B. S. S.; Poulos, T. L. Crystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal center Cell 1998, 95, 939-950
145. Ji, H.; Li, H.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping J. Med. Chem. 2009, 52, 779-797
146. Ji, H.; Stanton, B. Z.; Igarashi, J.; Li, H.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors J. Am. Chem. Soc. 2008, 130, 3900-3914
147. Ji, H.; Tan, S.; Igarashi, J.; Li, H.; Derrick, M.; Martásek, P.; Roman, L. J.; Vásquez-Vivar, J.; Poulos, T. L.; Silverman, R. B. Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy Ann. Neurol. 2009, 65, 209-217
148. Delker, S. L.; Ji, H.; Li, H.; Jamal, J.; Fang, J.; Xue, F.; Silverman, R. B.; Poulos, T. L. Unexpected binding modes of nitric oxide synthase inhibitors effective in the prevention of a cerebral palsy phenotype in an animal model J. Am. Chem. Soc. 2010, 132, 5437-5442
149. Ji, H.; Delker, S. L.; Li, H.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Exploration of the active site of neuronal nitric oxide synthase by the design and synthesis of pyrrolidinomethyl 2-aminopyridine derivatives J. Med. Chem. 2010, 53, 7804-7824
150. Xue, F.; Fang, J.; Delker, S. L.; Li, H.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Symmetric double-headed aminopyridines, a novel strategy for potent and membrane-permeable inhibitors of neuronal nitric oxide synthase J. Med. Chem. 2011, 54, 2039-2048
151. Faraci, W. S.; Nagel, A. A.; Verdries, K. A.; Vincent, L. A.; Xu, H.; Nichols, L. E.; Labasi, J. M.; Salter, E. D.; Pettipher, E. R. 2-Amino-4-methylpyridine as a potent inhibitor of inducible NO synthase activity in vitro and in vivo Br. J. Pharmacol. 1996, 119, 1101-1108
152. Hagmann, W. K.; Caldwell, C. G.; Chen, P.; Durette, P. L.; Esser, C. K.; Lanza, T. J.; Kopka, I. E.; Guthikonda, R.; Shah, S. K.; MacCoss, M.; Chabin, R. M.; Fletcher, D.; Grant, S. K.; Green, B. G.; Humes, J. L.; Kelly, T. M.; Luell, S.; Meurer, R.; Moore, V.; Pacholok, S. G.; Pavia, T.; Williams, H. R.; Wong, K. K. Substituted 2-aminopyridines as inhibitors of nitric oxide synthases Bioorg. Med. Chem. Lett. 2000, 10, 1975-1978
153. Lowe, J. A.; Qian, W.; Volkmann, R. A.; Heck, S.; Nowakowski, J.; Nelson, R.; Nolan, C.; Liston, D.; Ward, K.; Zorn, S.; Johnson, C.; Vanase, M.; Faraci, W. S.; Verdries, K. A.; Baxter, J.; Doran, S.; Sanders, M.; Ashton, M.; Whittle, P.; Stefaniak, M. A new class of selective and potent inhibitors of neuronal nitric oxide synthase Bioorg. Med. Chem. Lett. 1999, 9, 2569-2572
154. Lowe, J. A.; Qian, W.; Drozda, S. E.; Volkmann, R. A.; Nason, D.; Nelson, R. B.; Nolan, C.; Liston, D.; Ward, K.; Faraci, S.; Verdries, K.; Seymour, P.; Majchrzak, M.; Villalobos, A.; White, W. F. Structure-activity relationships of potent, selective inhibitors of neuronal nitric oxide synthase based on the 6-phenyl-2-aminopyridine structure J. Med. Chem. 2004, 47, 1575-1586
155. McCall, T. B.; Feelisch, M.; Palmer, R. M.; Moncada, S. Identification of N -iminoethyl- l -ornithine as an irreversible inhibitor of nitric oxide synthase in phagocytic cells Br. J. Pharmacol. 1991, 102, 234-238
156. Collins, J. L.; Shearer, B. G.; Oplinger, J. A.; Lee, S.; Garvey, E. P.; Salter, M.; Duffy, C.; Burnette, T. C.; Furfine, E. S. N -Phenylamidines as selective inhibitors of human neuronal nitric oxide synthase: structure-activity studies and demonstration of in vivo activity J. Med. Chem. 1998, 41, 2858-2871
157. Garvey, E. P.; Oplinger, J. A.; Furfine, E. S.; Kiff, R. J.; Laszlo, F.; Whittle, B. J.; Knowles, R. G. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo J. Biol. Chem. 1997, 272, 4959-4963
158. Maccallini, C.; Patruno, A.; Lannutti, F.; Ammazzalorso, A.; De Filippis, B.; Fantacuzzi, M.; Franceschelli, S.; Giampietro, L.; Masella, S.; Felaco, M.; Re, N.; Amoroso, R. N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase Bioorg. Med. Chem. Lett. 2010, 20, 6495-6499
159. Reif, D. W.; McCarthy, D. J.; Cregan, E.; Macdonald, J. E. Discovery and development of neuronal nitric oxide synthase inhibitors Free Radical Biol. Med. 2000, 28, 1470-1477
160. O'Neill, M. J.; Murray, T. K.; McCarty, D. R.; Hicks, C. A.; Dell, C. P.; Patrick, K. E.; Ward, M. A.; Osborne, D. J.; Wiernicki, T. R.; Roman, C. R.; Lodge, D.; Fleisch, J. H.; Singh, J. ARL 17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia Brain Res. 2000, 871, 234-244
161. Fedorov, R.; Vasan, R.; Ghosh, D. K.; Schlichting, I. Structures of nitric oxide synthase isoforms complexed with the inhibitor AR-R17477 suggest a rational basis for specificity and inhibitor design Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 5892-5897
162. Renton, P.; Green, B.; Maddaford, S. P.; Rakhit, S.; Andrews, J. S. Novel dual action neuronal nitric oxide synthase inhibitors with μ-opioid agonist activity ACS Med. Chem. Lett. 2012, 3, 227-231
163. Annedi, S. C.; Ramnauth, J.; Maddaford, S. P.; Renton, P.; Rakhit, S.; Mladenova, G.; Dove, P.; Silverman, S.; Andrews, J. S.; Felice, M. D.; Porreca, F. Discovery of cis-N -(1-(4-(methylamino)cyclohexyl)indolin-6-yl)thiophene-2- carboximidamide: a 1,6-disubstituted indoline derivative as a highly selective inhibitor of human neuronal nitric oxide synthase (nNOS) without any cardiovascular liabilities J. Med. Chem. 2012, 55, 943-955
164. Maddaford, S.; Annedi, S. C.; Ramnauth, J.; Rakhit, S. Advancements in the development of nitric oxide synthase inhibitors Annu. Rep. Med. Chem. 2009, 44, 27-50
165. Serafim, R. A.; Primi, M. C.; Trossini, G. H.; Ferreira, E. I. Nitric oxide: state of the art in drug design Curr. Med. Chem. 2012, 19, 386-405
166. Payne, J. E.; Bonnefous, C.; Symons, K. T.; Nguyen, P. M.; Sablad, M.; Rozenkrants, N.; Zhang, Y.; Wang, L.; Yazdani, N.; Shiau, A. K.; Noble, S. A.; Rix, P.; Rao, T. S.; Hassig, C. A.; Smith, N. D. Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-(2-cyclobutyl-1 H -imidazo[4,5- b ]pyrazin-1-yl)methyl)-7,8- difluoroquinolin-2(1 H)-one (KD7332). Part 2: Identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOS dimerization inhibitors that are orally active in pain models J. Med. Chem. 2010, 53, 7739-7755
167. Matter, H.; Kumar, H. S. A.; Fedorov, R.; Frey, A.; Kotsonis, P.; Hartmann, E.; Fröhlich, L. G.; Reif, A.; Pfleiderer, W.; Scheurer, P.; Ghosh, D. K.; Schlichting, I.; Schmidt, H. H. H. W. Structural analysis of isoform-specific inhibitors targeting the tetrahydrobiopterin binding site of human nitric oxide synthases J. Med. Chem. 2005, 48, 4783-4792
168. Behl, C. Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches Prog. Neurobiol. 1999, 57, 301-323
169. Christen, Y. Oxidative stress and Alzheimer disease Am. J. Clin. Nutr. 2000, 71, 621S-629S
170. Harman, D. A hypothesis on the pathogenesis of Alzheimer's disease Ann. N. Y. Acad. Sci. 1996, 786, 152-168
171. Joseph, J.; Shukitt-Hale, B.; Denisova, N. A.; Martin, A.; Perry, G.; Smith, M. A. Copernicus revisited: amyloid beta in Alzheimer's disease Neurobiol. Aging 2001, 22, 131-146
172. Markesbery, W. R.; Carney, J. M. Oxidative alterations in Alzheimer's disease Brain Pathol. 1999, 9, 133-146
173. Prasad, K. N.; Hovland, A. R.; Cole, W. C.; Prasad, K. C.; Nahreini, P.; Edwards-Prasad, J.; Andreatta, C. P. Multiple antioxidants in the prevention and treatment of Alzheimer disease: analysis of biologic rationale Clin. Neuropharmacol. 2000, 23, 2-13
174. Beal, M. F. Experimental models of Parkinson's disease Nat. Rev. Neurosci. 2001, 2, 325-334
175. Blum, D.; Torch, S.; Lambeng, N.; Nissou, M.; Benabid, A. L.; Sadoul, R.; Verna, J. M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease Prog. Neurobiol. 2001, 65, 135-172
176. Foley, P.; Riederer, P. Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease J. Neurol. 2000, 247 (Suppl. 2) II82-II94
177. Gerlach, M.; Riederer, P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man J. Neural Transm. 1996, 103, 987-1041
178. Browne, S. E.; Ferrante, R. J.; Beal, M. F. Oxidative stress in Huntington's disease Brain Pathol. 1999, 9, 147-163
179. Pedersen, W. A.; Fu, W.; Keller, J. N.; Markesbery, W. R.; Appel, S.; Smith, R. G.; Kasarskis, E.; Mattson, M. P. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients Ann. Neurol. 1998, 44, 819-824
180. Sayre, L. M.; Smith, M. A.; Perry, G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease Curr. Med. Chem. 2001, 8, 721-738
181. Grodstein, F.; Chen, J.; Willett, W. C. High-dose antioxidant supplements and cognitive function in community-dwelling elderly women Am. J. Clin. Nutr. 2003, 77, 975-984
182. Laurin, D.; Masaki, K. H.; Foley, D. J.; White, L. R.; Launer, L. J. Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia aging study Am. J. Epidemiol. 2004, 159, 959-967
183. Petersen, R. C.; Thomas, R. G.; Grundman, M.; Bennett, D.; Doody, R.; Ferris, S.; Galasko, D.; Jin, S.; Kaye, J.; Levey, A.; Pfeiffer, E.; Sano, M.; van Dyck, C. H.; Thal, L. J. Vitamin E and donepezil for the treatment of mild cognitive impairment N. Engl. J. Med. 2005, 352, 2379-2388
184. Hayden, K. M.; Welsh-Bohmer, K. A.; Wengreen, H. J.; Zandi, P. P.; Lyketsos, C. G.; Breitner, J. C. Risk of mortality with vitamin E supplements: the Cache County study Am. J. Med. 2007, 120, 180-184
185. Luchsinger, J. A.; Tang, M. X.; Shea, S.; Mayeux, R. Antioxidant vitamin intake and risk of Alzheimer disease Arch. Neurol. 2003, 60, 203-208
186. Sinha, K.; Chaudhary, G.; Gupta, Y. K. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats Life Sci. 2002, 71, 655-665
187. The Parkinson Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease N. Engl. J. Med. 1993, 328, 176-183
188. Kieburtz, K.; McDermott, M.; Como, P.; Growdon, J.; Brady, J.; Carter, J.; Huber, S.; Kanigan, B.; Landow, E.; Rudolph, A.; Saint-Cyr, J.; Stern, Y.; Tennis, M.; Thelen, J.; Shoulson, I.; Parkinson Study Group The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease Neurology 1994, 44, 1756-1759
189. Mihatsch, W.; Russ, H.; Gerlach, M.; Riederer, P.; Przuntek, H. Treatment with antioxidants does not prevent loss of dopamine in the striatum of MPTP-treated common marmosets: preliminary observations J. Neural Transm.: Parkinson's Dis. Dementia Sect. 1991, 3, 73-78
190. Perry, T. L.; Yong, V. W.; Hansen, S.; Jones, K.; Bergeron, C.; Foulks, J. G.; Wright, J. M. Alpha-tocopherol and beta-carotene do not protect marmosets against the dopaminergic neurotoxicity of N -methyl-4-phenyl-1,2,3,6- tetrahydropyridine J. Neurol. Sci. 1987, 81, 321-331
191. Peyser, C. E.; Folstein, M.; Chase, G. A.; Starkstein, S.; Brandt, J.; Cockrell, J. R.; Bylsma, F.; Coyle, J. T.; McHugh, P. R.; Folstein, S. E. Trial of d -alpha-tocopherol in Huntington's disease Am. J. Psychiatry 1995, 152, 1771-1775
192. Desnuelle, C.; Dib, M.; Garrel, C.; Favier, A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS Riluzole-Tocopherol Study Group Amyotrophic Lateral Scler. Other Mot. Neuron Disord. 2001, 2, 9-18
193. Gurney, M. E.; Cutting, F. B.; Zhai, P.; Doble, A.; Taylor, C. P.; Andrus, P. K.; Hall, E. D. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis Ann. Neurol. 1996, 39, 147-157
194. Asthana, S.; Baker, L. D.; Craft, S.; Stanczyk, F. Z.; Veith, R. C.; Raskind, M. A.; Plymate, S. R. High-dose estradiol improves cognition for women with AD: results of a randomized study Neurology 2001, 57, 605-612
195. Carlson, M. C.; Zandi, P. P.; Plassman, B. L.; Tschanz, J. T.; Welsh-Bohmer, K. A.; Steffens, D. C.; Bastian, L. A.; Mehta, K. M.; Breitner, J. C. Hormone replacement therapy and reduced cognitive decline in older women: the Cache County study Neurology 2001, 57, 2210-2216
196. Henderson, V. W.; Paganini-Hill, A.; Miller, B. L.; Elble, R. J.; Reyes, P. F.; Shoupe, D.; McCleary, C. A.; Klein, R. A.; Hake, A. M.; Farlow, M. R. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial Neurology 2000, 54, 295-301
197. Mulnard, R. A.; Cotman, C. W.; Kawas, C.; van Dyck, C. H.; Sano, M.; Doody, R.; Koss, E.; Pfeiffer, E.; Jin, S.; Gamst, A.; Grundman, M.; Thomas, R.; Thal, L. J. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's disease cooperative study JAMA, J. Am. Med. Assoc. 2000, 283, 1007-1015
198. Wang, P. N.; Liao, S. Q.; Liu, R. S.; Liu, C. Y.; Chao, H. T.; Lu, S. R.; Yu, H. Y.; Wang, S. J.; Liu, H. C. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study Neurology 2000, 54, 2061-2066
199. Blanchet, P. J.; Fang, J.; Hyland, K.; Arnold, L. A.; Mouradian, M. M.; Chase, T. N. Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study Neurology 1999, 53, 91-95
200. Fernandez, H. H.; Lapane, K. L. Estrogen use among nursing home residents with a diagnosis of Parkinson's disease Mov. Disord. 2000, 15, 1119-1124
201. Tsang, K. L.; Ho, S. L.; Lo, S. K. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations Neurology 2000, 54, 2292-2298
202. Baldereschi, M.; Di Carlo, A.; Rocca, W. A.; Vanni, P.; Maggi, S.; Perissinotto, E.; Grigoletto, F.; Amaducci, L.; Inzitari, D. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian longitudinal study on aging Neurology 2000, 55, 1358-1363
203. Mayeux, R.; Marder, K.; Cote, L. J.; Denaro, J.; Hemenegildo, N.; Mejia, H.; Tang, M. X.; Lantigua, R.; Wilder, D.; Gurland, B.; Hauser, A. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993 Am. J. Epidemiol. 1995, 142, 820-827
204. Aggarwal, B. B.; Harikumar, K. B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases Int. J. Biochem. Cell Biol. 2009, 41, 40-59
205. Richard, T.; Pawlus, A. D.; Iglesias, M. L.; Pedrot, E.; Waffo-Teguo, P.; Merillon, J. M.; Monti, J. P. Neuroprotective properties of resveratrol and derivatives Ann. N. Y. Acad. Sci. 2011, 1215, 103-108
206. Heim, K. E.; Tagliaferro, A. R.; Bobilya, D. J. Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships J. Nutr. Biochem. 2002, 13, 572-584
207. Pietta, P. G. Flavonoids as antioxidants J. Nat. Prod. 2000, 63, 1035-1042
208. Dickinson, D. A.; Forman, H. J. Cellular glutathione and thiols metabolism Biochem. Pharmacol. 2002, 64, 1019-1026
209. Owuor, E. D.; Kong, A. N. Antioxidants and oxidants regulated signal transduction pathways Biochem. Pharmacol. 2002, 64, 765-770
210. Filomeni, G.; Rotilio, G.; Ciriolo, M. R. Cell signalling and the glutathione redox system Biochem. Pharmacol. 2002, 64, 1057-1064
211. Paolicchi, A.; Dominici, S.; Pieri, L.; Maellaro, E.; Pompella, A. Glutathione catabolism as a signaling mechanism Biochem. Pharmacol. 2002, 64, 1027-1035
212. -•), superoxide dismutases, and related matters J. Biol. Chem. 1997, 272, 18515-18517
213. Masumoto, H.; Sies, H. The reaction of 2-(methylseleno)benzanilide with peroxynitrite Chem. Res. Toxicol. 1996, 9, 1057-1062
214. Parnham, M.; Sies, H. Ebselen: prospective therapy for cerebral ischaemia Expert Opin. Invest. Drugs. 2000, 9, 607-619
215. Moussaoui, S.; Obinu, M. C.; Daniel, N.; Reibaud, M.; Blanchard, V.; Imperato, A. The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease Exp. Neurol. 2000, 166, 235-245
216. Aitken, J. B.; Lay, P. A.; Duong, T. T.; Aran, R.; Witting, P. K.; Harris, H. H.; Lai, B.; Vogt, S.; Giles, G. I. Synchrotron radiation induced X-ray emission studies of the antioxidant mechanism of the organoselenium drug ebselen J. Biol. Inorg. Chem. 2012, 17, 589-598
217. d'Alessio, P.; Moutet, M.; Coudrier, E.; Darquenne, S.; Chaudiere, J. ICAM-1 and VCAM-1 expression induced by TNF-alpha are inhibited by a glutathione peroxidase mimic Free Radical Biol. Med. 1998, 24, 979-987
218. Moutet, M.; d'Alessio, P.; Malette, P.; Devaux, V.; Chaudiere, J. Glutathione peroxidase mimics prevent TNFalpha- and neutrophil-induced endothelial alterations Free Radical Biol. Med. 1998, 25, 270-281
219. Batinic-Haberle, I.; Benov, L.; Spasojevic, I.; Fridovich, I. The ortho effect makes manganese(III) meso-tetrakis(N -methylpyridinium-2-yl)porphyrin a powerful and potentially useful superoxide dismutase mimic J. Biol. Chem. 1998, 273, 24521-24528
220. Bowler, R. P.; Sheng, H.; Enghild, J. J.; Pearlstein, R. D.; Warner, D. S.; Crapo, J. D. A catalytic antioxidant (AEOL 10150) attenuates expression of inflammatory genes in stroke Free Radical Biol. Med. 2002, 33, 1141-1152
221. Patel, M.; Day, B. J. Metalloporphyrin class of therapeutic catalytic antioxidants Trends Pharmacol. Sci. 1999, 20, 359-364
222. Peng, J.; Mao, X. O.; Stevenson, F. F.; Hsu, M.; Andersen, J. K. The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway J. Biol. Chem. 2004, 279, 32626-32632
223. Peng, J.; Stevenson, F. F.; Doctrow, S. R.; Andersen, J. K. Superoxide dismutase/catalase mimetics are neuroprotective against selective paraquat-mediated dopaminergic neuron death in the substantial nigra: implications for Parkinson disease J. Biol. Chem. 2005, 280, 29194-29198
224. Young, A. J.; Lowe, G. M. Antioxidant and prooxidant properties of carotenoids Arch. Biochem. Biophys. 2001, 385, 20-27
225. Di Mascio, P.; Kaiser, S.; Sies, H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher Arch. Biochem. Biophys. 1989, 274, 532-538
226. Burton, G. W.; Ingold, K. U. beta-Carotene: an unusual type of lipid antioxidant Science 1984, 224, 569-573
227. Goodman, A. B.; Pardee, A. B. Evidence for defective retinoid transport and function in late onset Alzheimer's disease Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 2901-2905
228. Goodman, A. B. Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease J. Cell. Physiol. 2006, 209, 598-603
229. Ding, Y.; Qiao, A.; Wang, Z.; Goodwin, J. S.; Lee, E. S.; Block, M. L.; Allsbrook, M.; McDonald, M. P.; Fan, G. H. Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model J. Neurosci. 2008, 28, 11622-11634
230. Mann, K. G. Biochemistry and physiology of blood coagulation Thromb. Haemostasis 1999, 82, 165-174
231. Price, P. A. Role of vitamin-K-dependent proteins in bone metabolism Annu. Rev. Nutr. 1988, 8, 565-583
232. Allison, A. C. The possible role of vitamin K deficiency in the pathogenesis of Alzheimer's disease and in augmenting brain damage associated with cardiovascular disease Med. Hypotheses 2001, 57, 151-155
233. Beal, M. F.; Shults, C. W. Effects of coenzyme Q10 in Huntington's disease and early Parkinson's disease BioFactors 2003, 18, 153-161
234. Bhat, V.; Weiner, W. J. Parkinson's disease. Diagnosis and the initiation of therapy Minerva Med. 2005, 96, 145-154
235. Yang, X.; Yang, Y.; Li, G.; Wang, J.; Yang, E. S. Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation J. Mol. Neurosci. 2008, 34, 165-171
236. Yang, X.; Dai, G.; Li, G.; Yang, E. S. Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease J. Mol. Neurosci. 2010, 41, 110-113
237. Skulachev, V. P. Mitochondria-targeted antioxidants as promising drugs for treatment of age-related brain diseases J. Alzheimer's Dis. 2012, 28, 283-289
238. Szeto, H. H.; Schiller, P. W. Novel therapies targeting inner mitochondrial membrane-from discovery to clinical development Pharm. Res. 2011, 28, 2669-2679
239. Floyd, R. A.; Hensley, K. Nitrone inhibition of age-associated oxidative damage Ann. N. Y. Acad. Sci. 2000, 899, 222-237
240. Floyd, R. A.; Hensley, K.; Bing, G. Evidence for enhanced neuro-inflammatory processes in neurodegenerative diseases and the action of nitrones as potential therapeutics J. Neural Transm., Suppl. 2000, 387-414
241. Das, A.; Gopalakrishnan, B.; Voss, O. H.; Doseff, A. I.; Villamena, F. A. Inhibition of ROS-induced apoptosis in endothelial cells by nitrone spin traps via induction of phase II enzymes and suppression of mitochondria-dependent pro-apoptotic signaling Biochem. Pharmacol. 2012, 84, 486-497
242. Floyd, R. A.; Hensley, K.; Jaffery, F.; Maidt, L.; Robinson, K.; Pye, Q.; Stewart, C. Increased oxidative stress brought on by pro-inflammatory cytokines in neurodegenerative processes and the protective role of nitrone-based free radical traps Life Sci. 1999, 65, 1893-1899
243. Floyd, R. A.; Hensley, K.; Forster, M. J.; Kelleher-Andersson, J. A.; Wood, P. L. Nitrones, their value as therapeutics and probes to understand aging Mech. Ageing Dev. 2002, 123, 1021-1031
244. Shuaib, A.; Lees, K. R.; Lyden, P.; Grotta, J.; Davalos, A.; Davis, S. M.; Diener, H. C.; Ashwood, T.; Wasiewski, W. W.; Emeribe, U. NXY-059 for the treatment of acute ischemic stroke N. Engl. J. Med. 2007, 357, 562-571
245. Klivenyi, P.; Matthews, R. T.; Wermer, M.; Yang, L.; MacGarvey, U.; Becker, D. A.; Natero, R.; Beal, M. F. Azulenyl nitrone spin traps protect against MPTP neurotoxicity Exp. Neurol. 1998, 152, 163-166
246. Yang, L.; Calingasan, N. Y.; Chen, J.; Ley, J. J.; Becker, D. A.; Beal, M. F. A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities Exp. Neurol. 2005, 191, 86-93
247. Padayatty, S. J.; Katz, A.; Wang, Y.; Eck, P.; Kwon, O.; Lee, J. H.; Chen, S.; Corpe, C.; Dutta, A.; Dutta, S. K.; Levine, M. Vitamin C as an antioxidant: evaluation of its role in disease prevention J. Am. Coll. Nutr. 2003, 22, 18-35
248. Dringen, R.; Pfeiffer, B.; Hamprecht, B. Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione J. Neurosci. 1999, 19, 562-569
249. Dringen, R.; Hamprecht, B. N -Acetylcysteine, but not methionine or 2-oxothiazolidine-4-carboxylate, serves as cysteine donor for the synthesis of glutathione in cultured neurons derived from embryonal rat brain Neurosci. Lett. 1999, 259, 79-82
250. Cudkowicz, M. E.; Sexton, P. M.; Ellis, T.; Hayden, D. L.; Gwilt, P. R.; Whalen, J.; Brown, R. H., Jr. The pharmacokinetics and pharmaco-dynamics of procysteine in amyotrophic lateral sclerosis Neurology 1999, 52, 1492-1494
251. Dinkova-Kostova, A. T.; Holtzclaw, W. D.; Cole, R. N.; Itoh, K.; Wakabayashi, N.; Katoh, Y.; Yamamoto, M.; Talalay, P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11908-11913
252. Surh, Y. J.; Kundu, J. K.; Na, H. K. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals Planta Med. 2008, 74, 1526-1539
253. Magesh, S.; Chen, Y.; Hu, L. Q. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents Med. Res. Rev. 2012, 32, 687-726
254. Calkins, M. J.; Johnson, D. A.; Townsend, J. A.; Vargas, M. R.; Dowell, J. A.; Williamson, T. P.; Kraft, A. D.; Lee, J. M.; Li, J.; Johnson, J. A. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease Antioxid. Redox Signaling 2009, 11, 497-508
255. Jung, K. A.; Kwak, M. K. The Nrf2 system as a potential target for the development of indirect antioxidants Molecules 2010, 15, 7266-7291
256. Vargas, M. R.; Pehar, M.; Cassina, P.; Beckman, J. S.; Barbeito, L. Increased glutathione biosynthesis by Nrf2 activation in astrocytes prevents p75(NTR)-dependent motor neuron apoptosis J. Neurochem. 2006, 97, 687-696
257. Kirby, J.; Halligan, E.; Baptista, M. J.; Allen, S.; Heath, P. R.; Holden, H.; Barber, S. C.; Loynes, C. A.; Wood-Allum, C. A.; Lunec, J.; Shaw, P. J. Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS Brain 2005, 128, 1686-1706
258. Trinh, K.; Moore, K.; Wes, P. D.; Muchowski, P. J.; Dey, J.; Andrews, L.; Pallanck, L. J. Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease J. Neurosci. 2008, 28, 465-472
259. Ramsey, C. P.; Glass, C. A.; Montgomery, M. B.; Lindl, K. A.; Ritson, G. P.; Chia, L. A.; Hamilton, R. L.; Chu, C. T.; Jordan-Sciutto, K. L. Expression of Nrf2 in neurodegenerative diseases J. Neuropathol. Exp. Neurol. 2007, 66, 75-85
260. Stack, C.; Ho, D.; Wille, E.; Calingasan, N. Y.; Williams, C.; Liby, K.; Sporn, M.; Dumont, M.; Beal, M. F. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease Free Radical Biol. Med. 2010, 49, 147-158
261. Ross, C. A.; Poirier, M. A. Protein aggregation and neurodegenerative disease Nat. Med. 2004, 10 (Suppl.) S10-S17
262. Aguzzi, A.; O'Connor, T. Protein aggregation diseases: pathogenicity and therapeutic perspectives Nat. Rev. Drug Discovery 2010, 9, 237-248
263. Bartolini, M.; Andrisano, V. Strategies for the inhibition of protein aggregation in human diseases ChemBioChem 2010, 11, 1018-1035
264. Schneider, A.; Mandelkow, E. Tau based treatment strategies in neurodegenerative diseases Neurotherapeutics 2008, 5, 443-457
265. Shelton, S. B.; Johnson, G. V. Cyclin-dependent kinase-5 in neurodegeneration J. Neurochem. 2004, 88, 1313-1326
266. Hanger, D. P.; Anderton, B. H.; Noble, W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease Trends Mol. Med. 2009, 15, 112-119
267. Meijer, L.; Thunnissen, A. M. W. H.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L. H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. Z.; Biernat, J.; Mandelkow, E.; Kim, S. H.; Pettit, G. R. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent Chem. Biol. 2000, 7, 51-63
268. Palomo, V.; Perez, D. I.; Gil, C.; Martinez, A. The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy Curr. Med. Chem. 2011, 18, 3028-3034
269. Chen, P. C.; Gaisina, I. N.; El-Khodor, B. F.; Ramboz, S.; Makhortova, N. R.; Rubin, L. L.; Kozikowski, A. P. Identification of a maleimide-based glycogen synthase kinase-3 (GSK-3) inhibitor, BIP-135, that prolongs the median survival time of Delta 7 SMA KO mouse model of spinal muscular atrophy ACS Chem. Neurosci. 2012, 3, 5-11
270. Koh, S. H.; Kim, Y.; Kim, H. Y.; Hwang, S.; Lee, C. H.; Kim, S. H. Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS Exp. Neurol. 2007, 205, 336-346
271. Lin, X.; Parisiadou, L.; Gu, X. L.; Wang, L.; Shim, H.; Sun, L.; Xie, C.; Long, C. X.; Yang, W. J.; Ding, J.; Chen, Z. Z.; Gallant, P. E.; Tao-Cheng, J. H.; Rudow, G.; Troncoso, J. C.; Liu, Z.; Li, Z.; Cai, H. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein Neuron 2009, 64, 807-827
272. Ballatore, C.; Brunden, K. R.; Trojanowski, J. Q.; Lee, V. M.; Smith, A. B., 3rd; Huryn, D. M. Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies Curr. Top. Med. Chem. 2011, 11, 317-330
273. Wischik, C. M.; Edwards, P. C.; Lai, R. Y.; Roth, M.; Harrington, C. R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 11213-11218
274. Ballatore, C.; Crowe, A.; Piscitelli, F.; James, M.; Lou, K.; Rossidivito, G.; Yao, Y.; Trojanowski, J. Q.; Lee, V. M.; Brunden, K. R.; Smith, A. B., 3rd. Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties Bioorg. Med. Chem. 2012, 20, 4451-4461
275. Messing, L.; Decker, J. M.; Joseph, M.; Mandelkow, E.; Mandelkow, E. M. Cascade of tau toxicity in inducible hippocampal brain slices and prevention by aggregation inhibitors Neurobiol. Aging 2013, 34, 1343-1354
276. Ghosh, A. K.; Brindisi, M.; Tang, J. Developing beta-secretase inhibitors for treatment of Alzheimer's disease J. Neurochem. 2012, 120, 71-83
277. May, P. C.; Dean, R. A.; Lowe, S. L.; Martenyi, F.; Sheehan, S. M.; Boggs, L. N.; Monk, S. A.; Mathes, B. M.; Mergott, D. J.; Watson, B. M.; Stout, S. L.; Timm, D. E.; Smith Labell, E.; Gonzales, C. R.; Nakano, M.; Jhee, S. S.; Yen, M.; Ereshefsky, L.; Lindstrom, T. D.; Calligaro, D. O.; Cocke, P. J.; Greg Hall, D.; Friedrich, S.; Citron, M.; Audia, J. E. Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor J. Neurosci. 2011, 31, 16507-16516
278. D'Onofrio, G.; Panza, F.; Frisardi, V.; Solfrizzi, V.; Imbimbo, B. P.; Paroni, G.; Cascavilla, L.; Seripa, D.; Pilotto, A. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease Expert Opin. Drug Discovery 2012, 7, 19-37
279. Gillman, K. W.; Starrett, J. E.; Parker, M. F.; Xie, K.; Bronson, J. J.; Marcin, L. R.; McElhone, K. E.; Bergstrom, C. P.; Mate, R. A.; Williams, R.; Meredith, J. E.; Burton, C. R.; Barten, D. M.; Toyn, J. H.; Roberts, S. B.; Lentz, K. A.; Houston, J. G.; Zaczek, R.; Albright, C. F.; Decicco, C. P.; Macor, J. E.; Olson, R. E. Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable gamma-secretase inhibitor ACS Med. Chem. Lett. 2010, 1, 120-124
280. Panza, F.; Solfrizzi, V.; Frisardi, V.; Capurso, C.; D'Introno, A.; Colacicco, A. M.; Vendemiale, G.; Capurso, A.; Imbimbo, B. P. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators Drugs Aging 2009, 26, 537-555
281. Khan, T. K.; Nelson, T. J.; Verma, V. A.; Wender, P. A.; Alkon, D. L. A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Abeta-induced biomarker abnormality on cultured fibroblasts Neurobiol. Dis. 2009, 34, 332-339
282. Wender, P. A.; Baryza, J. L.; Brenner, S. E.; DeChristopher, B. A.; Loy, B. A.; Schrier, A. J.; Verma, V. A. Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 6721-6726
283. Simons, M.; Keller, P.; Dichgans, J.; Schulz, J. B. Cholesterol and Alzheimer's disease: Is there a link? Neurology 2001, 57, 1089-1093
284. Simons, M.; Schwarzler, F.; Lutjohann, D.; von Bergmann, K.; Beyreuther, K.; Dichgans, J.; Wormstall, H.; Hartmann, T.; Schulz, J. B. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial Ann. Neurol. 2002, 52, 346-350
285. Puglielli, L.; Tanzi, R. E.; Kovacs, D. M. Alzheimer's disease: the cholesterol connection Nat. Neurosci. 2003, 6, 345-351
286. Roy, A.; Pahan, K. Prospects of statins in Parkinson disease Neuroscientist 2011, 17, 244-255
287. Valenza, M.; Cattaneo, E. Emerging roles for cholesterol in Huntington's disease Trends Neurosci. 2011, 34, 474-486
288. Bate, C.; Tayebi, M.; Williams, A. Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation BMC Biol. 2008, 6, 8
289. Tobert, J. A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors Nat. Rev. Drug Discovery 2003, 2, 517-526
290. Arawaka, S.; Machiya, Y.; Kato, T. Heat shock proteins as suppressors of accumulation of toxic prefibrillar intermediates and misfolded proteins in neurodegenerative diseases Curr. Pharm. Biotechnol. 2010, 11, 158-166
291. Wyttenbach, A.; Arrigo, A. P. The Role of Heat Shock Proteins during Neurodegeneration in Alzheimer's, Parkinson's and Huntington's Disease. In Heat Shock Proteins in Neural Cells; Richter-Landsberg, C., Ed.; Springer and R. G. Landes: Georgetown, TX, U.S., 2009; p 125.
292. Neef, D. W.; Jaeger, A. M.; Thiele, D. J. Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases Nat. Rev. Drug Discovery 2011, 10, 930-944
293. Luo, W.; Sun, W.; Tadone, T.; Rodina, A.; Chiosis, G. Heat shock protein 90 in neurodegenerative diseases Mol. Neurodegener. 2010, 5, 24
294. Trott, A.; West, J. D.; Klaic, L.; Westerheide, S. D.; Silverman, R. B.; Morimoto, R. I.; Morano, K. A. Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule Mol. Biol. Cell 2008, 19, 1104-1112
295. Klaic, L.; Trippier, P. C.; Mishra, R. K.; Morimoto, R. I.; Silverman, R. B. Remarkable stereospecific conjugate additions to the Hsp90 inhibitor celastrol J. Am. Chem. Soc. 2011, 133, 19634-19637
296. Kieran, D.; Kalmar, B.; Dick, J. R.; Riddoch-Contreras, J.; Burnstock, G.; Greensmith, L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice Nat. Med. 2004, 10, 402-405
297. Evans, C. G.; Chang, L.; Gestwicki, J. E. Heat shock protein 70 (Hsp70) as an emerging drug target J. Med. Chem. 2010, 53, 4585-4602
298. Fleming, A.; Noda, T.; Yoshimori, T.; Rubinsztein, D. C. Chemical modulators of autophagy as biological probes and potential therapeutics Nat. Chem. Biol. 2011, 7, 9-17
299. Bove, J.; Martinez-Vicente, M.; Vila, M. Fighting neurodegeneration with rapamycin: mechanistic insights Nat. Rev. Neurosci. 2011, 12, 437-452
300. Casarejos, M. J.; Solano, R. M.; Gomez, A.; Perucho, J.; de Yebenes, J. G.; Mena, M. A. The accumulation of neurotoxic proteins, induced by proteasome inhibition, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma cells Neurochem. Int. 2011, 58, 512-520
301. Dennissen, F. J.; Kholod, N.; van Leeuwen, F. W. The ubiquitin proteasome system in neurodegenerative diseases: Culprit, accomplice or victim? Prog. Neurobiol. 2012, 96, 190-207
302. Luo, G.-R.; Chen, S.; Le, W.-D. Are heat shock proteins therapeutic target for Parkinson's disease? Int. J. Biol. Sci. 2007, 3, 20-26
303. Zhao, J. H.; Liu, H. L.; Lin, H. Y.; Huang, C. H.; Fang, H. W.; Chen, S. S.; Ho, Y.; Tsai, W. B.; Chen, W. Y. Chemical chaperone and inhibitor discovery: potential treatments for protein conformational diseases Perspect. Med. Chem. 2008, 1, 39-48
304. Ali, Y. O.; Kitay, B. M.; Zhai, R. G. Dealing with misfolded proteins: examining the neuroprotective role of molecular chaperones in neurodegeneration Molecules 2010, 15, 6859-6887
305. Cuajungco, M. P.; Faget, K. Y.; Huang, X.; Tanzi, R. E.; Bush, A. I. Metal chelation as a potential therapy for Alzheimer's disease Ann. N. Y. Acad. Sci. 2000, 920, 292-304
306. Wang, X.; Wang, X.; Zhang, C.; Jiao, Y.; Guo, Z. Inhibitory action of macrocyclic platiniferous chelators on metal-induced Ab aggregation Chem. Sci. 2012, 3, 1304-1312
307. Wisniewski, T.; Sadowski, M. Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors BMC Neurosci. 2008, 9 (Suppl. 2) S5
308. Simons, L. J.; Caprathe, B. W.; Callahan, M.; Graham, J. M.; Kimura, T.; Lai, Y.; LeVine, H., 3rd; Lipinski, W.; Sakkab, A. T.; Tasaki, Y.; Walker, L. C.; Yasunaga, T.; Ye, Y.; Zhuang, N.; Augelli-Szafran, C. E. The synthesis and structure-activity relationship of substituted N -phenyl anthranilic acid analogs as amyloid aggregation inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 654-657
309. Heiser, V.; Engernann, S.; Brocker, W.; Dunkel, I.; Boeddrich, A.; Waelter, S.; Nordhoff, E.; Lurz, R.; Schugardt, N.; Rautenberg, S.; Herhaus, C.; Barnickel, G.; Bottcher, H.; Lehrach, H.; Wanker, E. E. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 16400-16406
310. Geldenhuys, W. J.; Van der Schyf, C. J. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders Expert Opin. Drug Discovery 2013, 8, 115-129
311. Rizzo, S.; Tarozzi, A.; Bartolini, M.; Da Costa, G.; Bisi, A.; Gobbi, S.; Belluti, F.; Ligresti, A.; Allara, M.; Monti, J. P.; Andrisano, V.; Di Marzo, V.; Hrelia, P.; Rampa, A. 2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents Eur. J. Med. Chem. 2012, 58, 519-532
312. Sorrenti, V.; Salerno, L.; Di Giacomo, C.; Acquaviva, R.; Siracusa, M. A.; Vanella, A. Imidazole derivatives as antioxidants and selective inhibitors of nNOS Nitric Oxide 2006, 14, 45-50
313. Galdeano, C.; Viayna, E.; Sola, I.; Formosa, X.; Camps, P.; Badia, A.; Clos, M. V.; Relat, J.; Ratia, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Salmona, M.; Minguillon, C.; Gonzalez-Munoz, G. C.; Rodriguez-Franco, M. I.; Bidon-Chanal, A.; Luque, F. J.; Munoz-Torrero, D. Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases J. Med. Chem. 2012, 55, 661-669